Analysts forecast that Opko Health, Inc. (NASDAQ:OPK) will announce earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks. Three analysts have issued estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.03). Opko Health reported earnings of ($0.03) per share during the same quarter last year, which would indicate a negative year over year growth rate of 100%. The business is expected to announce its next quarterly earnings results on Monday, November 6th.

According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.20) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.14). For the next financial year, analysts expect that the company will report earnings of ($0.08) per share, with EPS estimates ranging from ($0.22) to $0.08. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm had revenue of $314.20 million for the quarter, compared to analyst estimates of $322.64 million. During the same period in the prior year, the firm posted $0.02 EPS. The company’s revenue for the quarter was down 12.0% on a year-over-year basis.

Several equities analysts have recently weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and issued a $6.50 price target (down from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $16.00 price target on shares of Opko Health in a research report on Monday, September 25th. Finally, Barrington Research lifted their price target on Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. Opko Health currently has a consensus rating of “Buy” and a consensus price target of $13.97.

Shares of Opko Health (NASDAQ:OPK) traded down 1.02% on Wednesday, reaching $6.81. The company’s stock had a trading volume of 3,830,895 shares. The firm’s 50 day moving average is $6.49 and its 200-day moving average is $6.72. The stock’s market cap is $3.81 billion. Opko Health has a 52-week low of $5.85 and a 52-week high of $12.15.

COPYRIGHT VIOLATION NOTICE: “-$0.06 Earnings Per Share Expected for Opko Health, Inc. (OPK) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/0-06-earnings-per-share-expected-for-opko-health-inc-opk-this-quarter.html.

In related news, CEO Phillip Md Et Al Frost bought 15,000 shares of the stock in a transaction dated Tuesday, September 19th. The stock was bought at an average price of $6.01 per share, with a total value of $90,150.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders bought 938,400 shares of company stock valued at $5,745,521. 40.19% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado increased its holdings in Opko Health by 0.3% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the biotechnology company’s stock valued at $483,000 after purchasing an additional 216 shares during the period. Pinnacle Associates Ltd. increased its holdings in Opko Health by 0.8% during the 2nd quarter. Pinnacle Associates Ltd. now owns 50,000 shares of the biotechnology company’s stock valued at $329,000 after purchasing an additional 397 shares during the period. Ameriprise Financial Inc. increased its holdings in Opko Health by 1.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 53,788 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 896 shares during the period. Envestnet Asset Management Inc. increased its holdings in Opko Health by 6.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 16,356 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,001 shares during the period. Finally, Van ECK Associates Corp increased its holdings in Opko Health by 1.5% during the 1st quarter. Van ECK Associates Corp now owns 83,984 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 1,274 shares during the period. Institutional investors own 22.46% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.